Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Q-Tuss is an over-the-counter (OTC) cough syrup developed and marketed by Shanur Healthcare, a South African pharmaceutical company. It is an oral liquid formulation primarily containing guaifenesin, an expectorant used for the symptomatic relief of coughs associated with upper respiratory tract infections. Guaifenesin works by increasing the volume and reducing the viscosity of respiratory tract secretions, thereby facilitating the removal of mucus from the airways through ciliary action and coughing. It is typically indicated for the treatment of productive or "wet" coughs and chest congestion. As a marketed consumer healthcare product, it is available without a prescription for the management of respiratory symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Q-Tuss.